The 2001 anthrax attacks in the US led to the emergence of biological terrorism as a public health, law enforcement, intelligence, and national security problem, highlighting the need for an integrated approach to addressing the threat. Advances in biotechnology, synthetic biology, and emerging technologies have defined the biological threat landscape over the past 25 years.

The deadly attacks of 11 September 2001 were followed by another critical terrorist incident in the United States, wherein anonymous letters laced with the deadly anthrax spores were sent to several media companies and post offices. The attacks claimed the lives of five people through the inhalation of anthrax and infected several others who came in contact with the postal envelopes. The Federal Bureau of Investigation (FBI) codenamed the investigation ‘Amerithrax’.[1] The ‘Amerithrax Task Force’ was created to determine the source of this terrorist attack. The FBI subsequently released an ‘Amerithrax Investigation Report’ detailing the course of the investigation.[2] The investigation focused primarily on scientists associated with the US biodefence establishment, especially the US Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland.

The investigation subsequently went through a series of phases which were deemed controversial. Several scientists were designated as ‘persons of interest’ and came under surveillance and investigation. In several cases, the suspects also pushed back against the allegations of deliberately releasing anthrax. One known suspect, Steven Hatfill, a pathologist and a biological weapons expert, ultimately received a large government settlement after pursuing legal action over being falsely accused in connection with the attacks.[3] In 2008, another biodefence scientist, Bruce Ivins, a senior biodefence researcher at USAMRIID who was identified as the principal suspect, died by suicide.[4] The FBI formally closed the investigation in 2010, concluding that Ivins was the actual culprit and that he had acted alone. However, an independent scientific review found that the evidence was consistent with Ivins being the culprit, but still inadequate to conclusively establish his responsibility.[5]

Along with the rapid investigations, the anthrax attacks also triggered a major national public health and law enforcement response, widespread disruption to postal services, and extensive decontamination efforts. Executed only a week after one of the worst terrorist attacks in modern history, the anthrax attacks added to the already heightened threat perceptions regarding terrorism. As a result of these attacks, biological terrorism emerged as a public health, law enforcement, intelligence, and national security problem, highlighting the need for an integrated approach to addressing the threat. Biological terrorism or bioterrorism, however, was not a novel phenomenon. There have been numerous accounts of non-state actors using or attempting to use hazardous biological materials as weapons to create widespread harm.[6]

This brief addresses response mechanisms, bio-surveillance, and emerging technology challenges to contextualise where the world stands today on bio-preparedness, 25 years after the 2001 Anthrax attacks. It explores the critical implications and opportunities for the Biological Weapons Convention (BWC) in shaping the future of global biosafety and biosecurity. The brief evaluates how two-and-a-half decades of science, technology, and policy evolution have shaped our preparedness against biological and toxic threats, and the challenges that persist.

Biodefence and Response Mechanisms

Response mechanisms and biodefence are a critical interdisciplinary field focused on protecting human life and agriculture. Key organisations involved include laboratories studying biological science, agricultural research centres, medical sciences, public health agencies, pharmaceutical companies, and national security agencies. Over the last 25 years, states worldwide have developed specific agencies associated with biological threats. Some states have developed advanced biodefence strategies and institutional mechanisms, while others are still working on them. It is also important to recognise that this threat has always been dynamic, so continued attention is required when deciding on response mechanisms and biodefence practices.

When it comes to addressing the risks posed by biological weapons, it is important to focus on the unique characteristics and vulnerabilities regarding biological agents. These agents include infectious pathogens and biotoxins that are non-transmissible. These weapons often have delayed effects and variable incubation periods, which add to the challenges of building robust response mechanisms for such threats. The case of anthrax attacks in the US made it fundamentally clear that investigations into biological weapons attacks are often met with attribution challenges. The challenge of effective attribution persists and is often exacerbated by rapid advances in biotechnology and easily accessible biological design tools.

The fragmented nature of biological weapons dissemination also challenges preparedness and response. While in the US, anthrax spores were dispersed through the postal mail, such agents can also be disseminated through aerosols or even contamination of important resources such as crops or water supplies, causing widespread damage. Therefore, as these threats rapidly evolve, delivery mechanisms for such agents are easily accessible to non-state actors, further complicating attribution.

The 2001 anthrax attacks exposed massive vulnerabilities in the public health detection and response systems, intelligence gathering, and inter-agency coordination mechanisms in the US. The US hence worked to build national capacities through the Public Health Security and Bioterrorism Preparedness Act of 2002 to strengthen prevention, preparedness, and response mechanisms against biothreats and to develop stringent standards for securing dangerous biological agents. The Act also imposed strict regulations on the possession, use, and handling of specific biological agents. To build on these response capabilities, Congress enacted the Project BioShield Act in 2004, which incentivised companies to research, develop, and stockpile medical countermeasures against CBRN threats.[7] Incentivising research in medical countermeasures also heightens capabilities to address novel bio-risks and leverage technological advancements to improve detection and response mechanisms.

Globally, funding surged for biodefence and preparedness research, as well as for high-containment facilities, to build scientific, defence, and policy capabilities to counter such threats.[8] The preparedness gaps to deal with bioterrorism threats were significantly highlighted in the aftermath of the anthrax attacks. The World Health Organization (WHO) developed the International Health Regulations in 2005 to legally require signatory countries to build national capacities for detecting, analysing, and surveilling public health emergencies of international concern.[9]

Additionally, the Global Health Security Initiative (GHSI) emerged in 2001 as a cross-regional multilateral grouping to improve cooperation in public health preparedness mechanisms to respond to CBRN terrorism threats, with WHO as the technical advisor.[10] The anthrax attacks thus led to growing........

© IDSA